C. Bingham

TL;DR: Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome and was also associated with improvement in health-related quality of life.

TL;DR: Key topics raised only by patients included possible reasons for stopping or modifying treatment, when to contact the provider, possibility of autoimmune disease progression or organ damage, sharing information with other providers, and lifestyle changes that can be done to help.

TL;DR: Goals relevant for RA treatment evaluation can be efficiently identified and rated for importance by patients and incorporated into deliberative healthcare valuation using this method to permit “crowd-sourced” input from people living with RA and to capture heterogeneous patient perspectives in healthcare valuation.

TL;DR: The findings of the updated PK analysis were consistent with those reported in prior population analyses of abatacept PK in adults with RA, and showed no increase in risk of infection with concomitant use of MTX and glucocorticoids.

TL;DR: To investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice leads to lower radiographic progression in RA, patients enrolled as they were initiating a new csDMARD/bDMARD treatment were followed-up with the intention to benchmark and intensify treatment.